GLP-1 Agonists May Lower Cirrhosis, Liver Cancer Risk in Type 2 Diabetes Patients

Study finds that individuals who took GLP-1 agonists for a long duration had a lower risk of going on to develop more severe forms of liver disease, including cirrhosis and liver cancer.